Barclays PLC Denali Therapeutics Inc. Transaction History

Barclays PLC

  • $353 Billion
  • Q1 2025

A detailed history of Barclays PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 240,648 shares of DNLI stock, worth $3.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
240,648
Previous 278,067 13.46%
Holding current value
$3.36 Million
Previous $5.67 Million 42.29%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025
SELL
$13.6 - $23.59 $508,898 - $882,714
-37,419 Reduced 13.46%
240,648 $3.27 Million
Q4 2024

Feb 13, 2025
BUY
$20.24 - $31.58 $449,004 - $700,570
22,184 Added 8.67%
278,067 $5.67 Million
Q3 2024

Nov 15, 2024
BUY
$20.96 - $31.05 $2.7 Million - $4 Million
128,823 Added 101.39%
255,883 $7.45 Million
Q2 2024

Aug 14, 2024
SELL
$14.96 - $23.22 $366,520 - $568,890
-24,500 Reduced 16.17%
127,060 $2.95 Million
Q1 2024

May 15, 2024
SELL
$15.83 - $23.35 $2.73 Million - $4.03 Million
-172,459 Reduced 53.22%
151,560 $3.11 Million
Q4 2023

Feb 15, 2024
BUY
$16.2 - $23.18 $2.55 Million - $3.65 Million
157,512 Added 94.6%
324,019 $6.95 Million
Q3 2023

Nov 07, 2023
BUY
$20.63 - $30.17 $165,968 - $242,717
8,045 Added 5.08%
166,507 $3.44 Million
Q2 2023

Aug 03, 2023
SELL
$23.37 - $32.96 $11.6 Million - $16.4 Million
-497,965 Reduced 75.86%
158,462 $4.68 Million
Q1 2023

May 04, 2023
BUY
$21.91 - $32.67 $1.54 Million - $2.3 Million
70,462 Added 12.02%
656,427 $15.1 Million
Q4 2022

Feb 13, 2023
BUY
$26.28 - $33.92 $6.85 Million - $8.84 Million
260,498 Added 80.04%
585,965 $16.3 Million
Q3 2022

Nov 03, 2022
SELL
$25.97 - $38.53 $1.12 Million - $1.67 Million
-43,304 Reduced 11.74%
325,467 $9.99 Million
Q2 2022

Aug 12, 2022
BUY
$20.88 - $35.19 $6.49 Million - $10.9 Million
310,639 Added 534.37%
368,771 $10.9 Million
Q1 2022

May 16, 2022
SELL
$29.0 - $47.27 $1.82 Million - $2.96 Million
-62,689 Reduced 51.89%
58,132 $1.87 Million
Q4 2021

Feb 14, 2022
BUY
$42.59 - $55.02 $2.12 Million - $2.74 Million
49,856 Added 70.25%
120,821 $5.39 Million
Q3 2021

Nov 09, 2021
BUY
$48.48 - $78.23 $2.29 Million - $3.69 Million
47,204 Added 198.66%
70,965 $3.58 Million
Q2 2021

Aug 13, 2021
SELL
$50.3 - $78.44 $3.32 Million - $5.18 Million
-66,012 Reduced 73.53%
23,761 $1.87 Million
Q1 2021

May 13, 2021
BUY
$53.8 - $81.53 $3.62 Million - $5.49 Million
67,315 Added 299.74%
89,773 $5.13 Million
Q4 2020

Feb 11, 2021
SELL
$36.89 - $93.56 $234,472 - $594,667
-6,356 Reduced 22.06%
22,458 $1.88 Million
Q3 2020

Nov 12, 2020
SELL
$23.13 - $38.84 $156,705 - $263,141
-6,775 Reduced 19.04%
28,814 $1.03 Million
Q2 2020

Aug 12, 2020
BUY
$16.01 - $28.82 $282,080 - $507,779
17,619 Added 98.05%
35,589 $860,000
Q1 2020

May 13, 2020
SELL
$14.2 - $27.98 $435,911 - $858,930
-30,698 Reduced 63.08%
17,970 $314,000
Q4 2019

Feb 10, 2020
BUY
$14.4 - $19.99 $60,739 - $84,317
4,218 Added 9.49%
48,668 $848,000
Q3 2019

Nov 14, 2019
BUY
$15.32 - $21.92 $207,402 - $296,752
13,538 Added 43.8%
44,450 $681,000
Q2 2019

Aug 14, 2019
BUY
$18.5 - $28.14 $317,904 - $483,557
17,184 Added 125.17%
30,912 $642,000
Q1 2019

May 15, 2019
BUY
$17.99 - $24.65 $246,966 - $338,395
13,728 New
13,728 $319,000
Q4 2018

Feb 14, 2019
SELL
$13.88 - $21.75 $236,945 - $371,294
-17,071 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$12.46 - $21.74 $197,279 - $344,209
15,833 Added 1278.92%
17,071 $371,000
Q2 2018

Aug 14, 2018
SELL
$15.25 - $21.02 $32,009 - $44,120
-2,099 Reduced 62.9%
1,238 $19,000
Q1 2018

May 15, 2018
BUY
$15.36 - $24.8 $51,256 - $82,757
3,337 New
3,337 $65,000

Others Institutions Holding DNLI

# of Institutions
234
Shares Held
127M
Call Options Held
37.3K
Put Options Held
7.9K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $1.87B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email